Compare Neurocrine Biosciences Inc (NBIX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Western Digital Corp — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Western Digital Corp trades at $478.57 (market cap $172.09B). The key difference: Western Digital Corp is far larger — about 10.9× Neurocrine Biosciences Inc's market cap, and Western Digital Corp pays a 0.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WDC | |
|---|---|---|
Market Cap | $15.77B | $172.09B |
Sector | Health | Technology |
52-Week High | $185.50 | $746.23 |
52-Week Low | $123.10 | $95.03 |
Enterprise Value | $15.78B | $171.56B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Western Digital (WDC) trades at $477.30, up 2.1% today, reflecting strong momentum amid AI-driven storage demand. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $676.70 suggesting 42% upside. Fundamentals are robust, with a net income margin of 71.97% in 2025 and positive cash flow trends, though revenue declined to $9.52B from prior years.
Outlook remains positive due to AI data growth catalysts and shareholder returns, but risks include competitive pressures and volatility from high expectations. The stock's valuation multiples like P/E of 17.73 appear reasonable given growth prospects, supporting a bullish bias with caution on execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
